59 completed, 5 unknown, 1 terminated, 1 withdrawn. 33 Phase 3, 18 Phase 2, 6 Phase 4, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 33 | Completed 31, Terminated 1, Withdrawn 1 |
| Phase 2 | 18 | Completed 17, Unknown 1 |
| Phase 4 | 6 | Completed 4, Unknown 2 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 1 | Completed 1 |
Follow ombitasvir: new trials by email Literature Review of ombitasvir trials Research Report on ombitasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C Direct-acting antiviral agents - Hepatitis C, Chronic | Unknown | Qing XIe | 300 | 2019-03-06 | 2021-07-07 | |
| Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet - End-stage Renal Disease, HCV Coinfection | Phase 4 | Completed | Assiut University | 110 | 2018-05-01 | 2020-01-10 |
| Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure Sofosbuvir, Simeprevir, Daclatasvir - HCV Coinfection | Not applicable | Completed | Assiut University | 40 | 2018-01-01 | 2019-03-19 |
| Effect Of DAAs For Treatment Of HCV On Normal Kidney Sofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir - Antiviral Drug Adverse Reaction | Phase 4 | Unknown | Assiut University | 100 | 2017-10-01 | 2017-09-29 |
| Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients SOF plus (OBV/PTV/r) plus RBV - Chronic Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 113 | 2017-03-01 | 2020-05-18 |
| Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks - Hepatitis C Infection | Completed | Hepa C | 200 | 2017-02-20 | 2018-05-21 | |
| Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4 OBV/PTV/r) ± ribavirin (RBV) - Hepatitis C Virus Infection | Phase 1 / Phase 2 | Completed | Beni-Suef University | 100 | 2017-01-05 | 2020-05-12 |
| Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients Ombitasvir, Paritaprevir and Ritonavir - Chronic Hepatitis c | Phase 2 | Unknown | Ain Shams University | 40 | 2016-11-09 | 2018-01-18 |
| Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) Ombitasvir/paritaprevir/ritonavir - Chronic Hepatitis C Virus | Phase 3 | Withdrawn | AbbVie | 2016-09-01 | 2016-12-05 | |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 256 | 2016-07-07 | 2019-10-11 | |
| Study of Oral Treatments for Hepatitis C SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir) - Chronic Hepatitis C | Phase 4 | Completed | University of Florida | 1275 | 2016-06-01 | 2021-12-06 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 216 | 2016-04-05 | 2019-03-15 | |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection ABT-493/ABT-530, OBV/PTV/r - Chronic Hepatitis C Virus, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 295 | 2016-02-22 | 2021-07-16 |
| A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults ombitasvir/paritaprevir/ritonavir, dasabuvir - Hepatitis C Infection, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 166 | 2015-11-24 | 2021-07-30 |
| The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 101 | 2015-11-05 | 2019-05-06 | |
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | AbbVie | 64 | 2015-10-28 | 2021-10-05 |
| Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 105 | 2015-10-28 | 2019-12-10 |
| Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C | Completed | AbbVie | 565 | 2015-10-13 | 2019-03-27 | |
| Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C, Genotype 1 or 4 | Completed | AbbVie | 314 | 2015-10-07 | 2019-05-06 | |
| Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 18 | 2015-09-30 | 2017-12-04 |
Showing 20 of 66. Sign in to see all of them.
Hepatitis C (49) · Hepatitis C, Chronic (43) · Fibrosis (7) · Kidney Diseases (3) · Kidney Failure, Chronic (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis, Chronic (2) · Infections (2) · Renal Insufficiency (2) · HIV Infections (1) · Renal Insufficiency, Chronic (1)
AbbVie (37) · AbbVie (prior sponsor, Abbott) (13) · Assiut University (3) · Beni-Suef University (2) · Valme University Hospital (2) · Abbott (1) · Ain Shams University (1) · Hepa C (1) · Kaiser Permanente (1) · National Taiwan University Hospital (1) · Nova Scotia Health Authority (1) · Ottawa Hospital Research Institute (1) · Qing XIe (1) · University of Florida (1)
United States (8) · Spain (6) · Egypt (4) · Canada (3) · Germany (3) · Puerto Rico (3) · Australia (2) · Belgium (2) · France (2) · Israel (2) · United Kingdom (2) · Algeria (1) · Austria (1) · Bulgaria (1) · China (1)
Eric Cohen, MD (4) · Andrew Campbell, MD (2) · Dan Cohen, MD (2) · Emily Dumas, PhD (2) · Roger Trinh, MD (2) · Yan Luo, MD (2) · Andrew L Campbell, MD (1) · Armen Asatryan, MD (1) · Daniel Cohen, MD (1) · David R Nelson, MD (1) · Georgios Mitas, MS (1) · Jeff Enejosa, MD (1)
PMID 29377566, PMID 30739368, PMID 26321288, PMID 26596948, PMID 29909549, PMID 30291369, PMID 30853642, PMID 37671831, PMID 24428468, PMID 24720679, PMID 24720703, PMID 24818763, PMID 25386767, PMID 25451055, PMID 25644279, PMID 25839406, PMID 26083155, PMID 26100711, PMID 26147154, PMID 26248955, PMID 26711747, PMID 26743093, PMID 26976799, PMID 27084721, PMID 27115431, PMID 27415157, PMID 27762283, PMID 27882706, PMID 27919899, PMID 28004322, PMID 28128852, PMID 28137633, PMID 28404108, PMID 28412293, PMID 28599618, PMID 28842997, PMID 28865152, PMID 28941361, PMID 29180522, PMID 29377515, PMID 29546644, PMID 30012435, PMID 30160363, PMID 30858739, PMID 30868245, PMID 30923816, PMID 30977945, PMID 30980576, PMID 31568620, PMID 31790766
2014 (7), 2015 (5)